Key statistics dashboard for Lexeo Therapeutics, Inc. Common Stock (LXEO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
Stock Data
| Price | $4.16 |
| Market Cap | $327M |
| Enterprise Value | $240.6M |
| Beta | 2.00 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.62 |
| Price / Book | 1.52 |
| P/S | 0.00 |
| EV/EBITDA | -2.82 |
| EV/Sales | 0.00 |
| EV/FCF | -2.71 |
| P/FCF | -3.69 |
| Earnings Yield | -24.50% |
| FCF Yield | -27.15% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -41.85% |
| Return on Assets | -34.24% |
| Return on Invested Capital | -39.33% |
| Return on Capital Employed | -39.76% |
Financial Health
| Current Ratio | 13.89 |
| Quick Ratio | 13.89 |
| Cash Ratio | 5.92 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.67% |
| Net Debt / EBITDA | 1.01 |
| Interest Coverage | -689.25 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.75 |
| Cash per share | 2.47 |
| FCF per share | -1.04 |
| Tangible Book Value per share | 2.75 |
| Dividend per share | 0.00 |
Related companies: AMRN · CAPR · CTNM · DBVT · KYTX · LRMR · MREO
Explore sector: Healthcare · Biotechnology
More sections of LXEO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks